Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: An applicator assembly includes a head portion having a proximal, a distal end, and an interior portion defining a fluid chamber, a container slidably coupled to the body, a sealing member sealing an end of the container, and a lifting member, wherein the lifting member is mounted in the interior portion of the head portion and an interior of the container is placed in fluid communication with the application member by way of a fluid conduit that is formed around the sealing member from the container to the fluid chamber when the container is axially translated toward the head portion and the lifting member lifts the sealing member.

Abstract: An applicator assembly includes a head portion having a proximal, a distal end, and an interior portion defining a fluid chamber, a container slidably coupled to the body, a sealing member sealing an end of the container, and a lifting member, wherein the lifting member is mounted in the interior portion of the head portion and an interior of the container is placed in fluid communication with the application member by way of a fluid conduit that is formed around the sealing member from the container to the fluid chamber when the container is axially translated toward the head portion and the lifting member lifts the sealing member.

Abstract: The present invention relates to phytocannabinoids for use in the treatment of a breast cancer. In a first embodiment the invention relates to an oral presentation of tetrahydrocannabinol (THC) for use in the treatment of aggressive breast cancer, characterised by overexpression of the Her2 gene. In a second embodiment the invention relates to the phytocannabinoid cannabidiol (CBD) for use in the treatment of aggressive breast cancer, characterised by overexpression of the Her2 gene. In a third embodiment the invention relates to the combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use in the treatment of breast cancer or to treat, prevent or to reduce the risk of a cancer metastasising.

Abstract: An applicator assembly includes a body defining a pocket, a closed ampoule received in the pocket, an integrated protective device attached to the body and enclosing the pocket, a lever projecting from the body, at least one tappet that bears against an external surface of the pocket and fractures the ampoule when the lever is pivoted, and an application member secured to the body, wherein an interior of the pocket is placed in fluid communication with the application member by way of through-holes provided in the integrated protective device. A method for manufacturing the applicator assembly includes rotating the protective device from an open position into a closed position to enclose the ampoule in the pocket before the application member is attached to the body so that the fluid to be dispensed will flow through the protective device and contact the application member when the ampoule is fractured.

Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).

Abstract: An applicator assembly includes a head portion having a proximal, a distal end, and an interior portion defining a fluid chamber, a container slidably coupled to the body, a breakable membrane sealing an end of the container, and a hollow puncture mechanism, wherein the hollow puncture mechanism is mounted in the interior portion of the head portion and an interior of the container is placed in fluid communication with the application member by way of a fluid conduit that is formed through the hollow puncture mechanism from the container to the fluid chamber when the container is axially translated toward the head portion and the puncture mechanism pierces the breakable membrane.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: An applicator assembly includes a body having a proximal and a distal end, a container slidably coupled to the body, a valve cap coupled to the container, and an application member attached to the distal end, wherein an interior of the container is placed in fluid communication with the application member by way of a fluid conduit that is only accessible when one of the body and the container are axially translated in an opposite direction away from each other.

Abstract: An applicator assembly includes a body having a proximal and a distal end, a container slidably coupled to the body, a valve cap coupled to the container, and an application member attached to the distal end, wherein an interior of the container is placed in fluid communication with the application member by way of a fluid conduit that is only accessible when one of the body and the container are axially translated in an opposite direction away from each other.

Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumor, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).

Abstract: An applicator assembly includes a container having a proximal end, a distal end, and an interior portion defining a chamber, an application member attached to the distal end of the container, and a tearable solution reservoir disposed within the chamber, the tearable solution reservoir comprising a tearing member, wherein actuating the tearing member to tear the tearable solution reservoir brings the container, the tearable solution reservoir, and the application member into fluid communication with each other.

Abstract: An applicator assembly includes a head portion having a proximal end, a distal end, and an interior portion defining a fluid chamber, a container slidably coupled to the head portion, a plug sealing an end of the container, an application member attached to the distal end, and one or more orifices formed through a surface of the plug, wherein the plug is mounted in the interior portion of the head portion and an interior of the container is placed in fluid communication with the application member by way of a fluid conduit that is formed through the plug from the container to the fluid chamber when the container is axially translated toward the head portion to bring the one or more orifices into fluid communication with the container

Abstract: An applicator assembly includes a head portion having a proximal, a distal end, and an interior portion defining a fluid chamber, a container slidably coupled to the body, a sealing member sealing an end of the container, and a lifting member, wherein the lifting member is mounted in the interior portion of the head portion and an interior of the container is placed in fluid communication with the application member by way of a fluid conduit that is formed around the sealing member from the container to the fluid chamber when the container is axially translated toward the head portion and the lifting member lifts the sealing member.

Abstract: An applicator assembly includes a head portion having a proximal, a distal end, and an interior portion defining a fluid chamber, a container slidably coupled to the body, a breakable membrane sealing an end of the container, and a hollow puncture mechanism, wherein the hollow puncture mechanism is mounted in the interior portion of the head portion and an interior of the container is placed in fluid communication with the application member by way of a fluid conduit that is formed through the hollow puncture mechanism from the container to the fluid chamber when the container is axially translated toward the head portion and the puncture mechanism pierces the breakable membrane.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: An applicator assembly includes a body defining a pocket, a closed ampoule received in the pocket, an integrated protective device attached to the body and enclosing the pocket, a lever projecting from the body, at least one tappet that bears against an external surface of the pocket and fractures the ampoule when the lever is pivoted, and an application member secured to the body, wherein an interior of the pocket is placed in fluid communication with the application member by way of through-holes provided in the integrated protective device. A method for manufacturing the applicator assembly includes rotating the protective device from an open position into a closed position to enclose the ampoule in the pocket before the application member is attached to the body so that the fluid to be dispensed will flow through the protective device and contact the application member when the ampoule is fractured.

Abstract: An applicator assembly includes a body having a proximal and a distal end, a container slidably coupled to the body, a valve cap coupled to the container, and an application member attached to the distal end, wherein an interior of the container is placed in fluid communication with the application member by way of a fluid conduit that is only accessible when one of the body and the container are axially translated in an opposite direction away from each other.

Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).